Vir Biotechnology/$VIR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Ticker

$VIR
Primary listing

Industry

Biotechnology

Employees

408

VIR Metrics

BasicAdvanced
$781M
-
-$4.22
1.23
-

What the Analysts think about VIR

Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.

Bulls say / Bears say

Vir Biotechnology's strong cash position, with cash and equivalents of $273.6 million and short-term investments of $528.1 million as of Q1 2025, provides financial flexibility for ongoing operations and R&D investments. (marketbeat.com)
The company's exclusive worldwide license agreement with Sanofi, finalized in September 2024, grants access to three clinical-stage masked T-cell engagers, potentially enhancing its oncology pipeline. (finance.yahoo.com)
Positive results from the SOLSTICE Phase 2 clinical trial for chronic hepatitis delta, with 80% virologic response at Week 60, support the initiation of the Phase 3 ECLIPSE registrational program in early 2025. (stocktitan.net)
Vir Biotechnology reported a 94.6% year-over-year decline in total revenue to $3.03 million in Q1 2025, primarily due to the expiration of COVID-related product sales. (marketbeat.com)
The company announced a workforce reduction of approximately 25% in August 2024, indicating a strategic shift away from infectious disease research, which may impact future growth prospects. (medicalupdateonline.com)
Vir Biotechnology's net loss widened to $120.965 million in Q1 2025 from $65.276 million in Q1 2024, reflecting ongoing unprofitability and increased R&D expenses. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

VIR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VIR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VIR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs